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Abstract
Introduction: In 2025, more than 400 million people will have asthma, and chronic obstructive pulmonary disease (COPD) will be
the third leading cause of death by 2030. This trial, called better outcomes for everybody, will evaluate the effectiveness and cost-
effectiveness of a pharmacist-led intervention delivered by community pharmacists in collaboration with physicians to asthma and
COPD patients to improve disease control compared with usual care.
Methods:A pragmatic parallel 2-arm randomized controlled trial will be conducted in one Italian region (Sicily). A 2:1 randomization
and sample size of 900 adult patients (450 with asthma, 450 with COPD) will be sufficient to detect a difference of 15% between the
intervention and control groups using a dichotomized score (controlled versus non-controlled) of the Asthma Control Test (ACT) and
the Clinical Chronic Obstructive Pulmonary Disease Questionnaire (CCQ) with a two-tails, 99% power and 5% significance level. A
hundred pharmacists will recruit 9 consecutive patients each and administer either ACT or CCQ according to the patients’ disease.
Patients will be followed up for 12months, and the pharmacists will meet their patients every three months. The control group will
receive usual care, the intervention a bespoke, structured, and systematic consultation immediately after baseline and 6months later.
The primary outcomes are asthma and COPD control at baseline and 12months. Secondary outcomes: risk of uncontrolled asthma
and COPD, number of active ingredients, pharmaceutical care issues, adherence to medications, minimal clinically important
differences in asthma and COPD, and a full health economic evaluation. The analysis will follow an intention-to-treat principle.
Generalized estimating equations will be used to test the primary outcomes. Ethics approval was obtained.
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Discussion: This is the first study conducted in Italy to assess the effectiveness and cost-effectiveness of a pharmacist-led
intervention in asthma and COPD patients at the same time. This research could introduce a new model of care that can be adapted
to other chronic conditions in primary care settings. The results will be disseminated to service users and their families via media,
healthcare professionals via professional training and meetings, and researchers via conferences and publications.
Trial registration: ISRCTN, ID: 38734433 Registered on June 15, 2021
Abbreviations: ACT = asthma control test, CCQ = clinical COPD questionnaire, CG = control group, CI = chief investigator,
COPD = chronic obstructive pulmonary disease, COVID-19 = coronavirus, CRC-MUR = chronic respiratory conditions medicines
use review, EQ-5D-5L = EuroQol Five Dimensions Five Levels, GDPR = General Data Protection Regulation, GEE = Generalized
Estimating Equation, HEREMOS = Health REmote MOnitoring System, I-MUR = Italian Medicines Use Review, MCID = minimal
clinically important difference, MUR = Medicines Use Review, NNT = number needed to treat, QALY = Quality Adjusted Life Year,
RCT = randomized controlled trial.
Keywords: asthma, community pharmacy, chronic obstructive pulmonary disease, cost-effectiveness, effectiveness, randomized
controlled trial
1. Introduction
1.1. Background and rationale
The health burden of chronic respiratory disease suggests that in
2017, 544.9 million people worldwide had a chronic respiratory
disease, representing an increase of 39.8% compared to 1990.[1]
The most recent revised global estimate of asthma suggests that as
many as 334 million people have asthma, the burden of disability
is high.[2] With a projected surge in the world’s urban population,
it is estimated that by 2025, an additional 100million people may
develop asthma.[3] Hence, asthma is becoming one of the most
prevalent chronic diseases worldwide. The prevalence of chronic
obstructive pulmonary disease (COPD) varies according to
country, age, and sex, and increases with age due to increased life
expectancy.[4] Moreover, infections seem to play an essential role
in COPD occurrence; repeated exacerbations, viral or bacterial,
could also contribute to lung function decline.[5]
Since the onset of the coronavirus (COVID-19) pandemic in
2020, patients and primary care practitioners have canceled or
postponed visits and appointments due to a shortage of
healthcare resources and the risk of infection.[6] The full impact
of COVID-19 on society and the economy is not fully
understood. Still, it has been estimated that the gross domestic
product (GDP) will decline by about 5% for each month of
partial economic shutdown, which equates to 1.07 trillion dollars
in the United States of America.[7] The COVID-19 outbreak poses
a major threat to patients suffering from chronic lung conditions.
Some researchers and institutions suggest that uncontrolled
asthma could increase the risk of COVID-19,[8,9] and the same
applies to COPD.[10]
Asthma and COPD erode the health and well-being of patients
and harm families and societies.[3] The total cost of respiratory
conditions accounts for more than €380 billion annually in
Europe, which includes the costs of primary and hospital care
(€55 billion), the cost of productivity loss due to sickness (€42
billion), and the monetized value of disability-adjusted life-years
lost (€280 billion). Healthcare costs and lost productivity due to
COPD are estimated at €48.4 billion. Those due to asthma
amounted to €33.9 billion per year.[11] A link between disease
control (asthma[12] and COPD[13]) and costs to the National
Health Service and society has been demonstrated. The treatment
of chronic disease includes the long-term use of medication,[14]
which applies to asthma and COPD. The National Institute for
Care andClinical Excellence issued guidelines regardingmedicine
optimization, a person-centered approach to safe and effective
medicine use, to ensure that people obtain the best possible
outcomes from their medicines.[15,16]
Nevertheless, the use of medications without support is not
sufficient for patients to achieve good clinical outcomes, quality
of life, and cost containment.[11] Practitioners working in primary
care are well placed to provide support for their patients, and
community pharmacists are easily accessible even during the
COVID-19 outbreak.[17] An activity often undertaken by
community pharmacists to help people improve their use of
medication is the medicine use review, which is considered a
complex intervention according to Craig et al.[18] The evaluation
of this intervention is far from easy. A recent systematic literature
review, published in 2019, pointed out that an “ideal” method
for evaluating complex interventions cannot be proposed.
Instead, methods can be used according to the research questions
that need to be addressed.[19] Besides objective outcomemeasures
(e.g., blood tests, smoking status, date of death), patient-reported
outcome measures in clinical practice have the potential to
enhance care for people by identifying problems and improving
patient–clinician communication.[20]
One of the earliest funded advanced pharmacy services in
England was the Medicines Use Review (MUR) introduced in
2005, which up until now, showed little evidence to support either
its effectiveness or cost-effectiveness.[21,22] In 2017, a systematic
review and meta-analysis of randomized controlled trials (RCTs)
of medication review suggested that an isolated medication review
hasminimal effect on clinical outcomes, no impact on thequality of
life, and lack evidence of economic outcomes. However, studies
have shownadecrease in the number of drug-related problems and
dosage, more changes in medication, and a greater decrease or
smaller increase in the number of medications used.[23] Newman
et al[24] evaluated the impact of community pharmacist-led
interventions in chronic diseasemanagement on clinical utilization
and economic outcomes. Other positive results were identified in
other reviews,[25–27] but more robust studies are needed to assess
their economic outcomes.[28]
In 2012, the Italian Pharmacists’ Federation founded a
research project called Italian Medicines Use Review (I-MUR),
aiming to develop, test, and evaluate the effectiveness and cost of
the first community pharmacist-led intervention using asthma as
a chronic condition. The Medical Research Council framework
for complex intervention informed the development of I-MUR,
which was conducted in different steps: 1) a literature review, 2)
development and testing, 4) feedback from the main stake-
holders, 5) evaluation, and 6) further analysis.[29–32]
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The success of the I-MUR project raised the pharmacy
profession’s profile to a new challenge: the introduction anddelivery
of these services at the national level. The results of the project
significantly impacted policy and practice, and the Italian govern-
ment allocated funds for such services. Following this experience,
SOFAD srl (the sponsor), part of the FARVIMA group, a privately
owned company and its stakeholders, decided to provide funds to
explore the possibility of developing a pharmacist-led intervention
that can be used for asthma and COPD patients as well.
A Belgian study suggested that pharmacists could improve
outcomes in patients with COPD.[26] Hesso et al[33] assessed the
impact of pharmacists on COPD management, looking at
inhalation technique and medication adherence; the results
demonstrated that these activities were cost-effective. In India, a
study evaluated the direct impact of clinical pharmacist
interventions on medicine costs in patients suffering from COPD.
The study was an RCT conducted for 24months; the results
showed a reduction of 30.6% in the cost of medicines.[34] The
United States is suggesting an emerging role for pharmacists in
managing patients with COPD.[35] Pharmacists’ roles are
evolving, and they seem to work increasingly more often as
part of multidisciplinary care teams.[35]
Asthma control is important because it improves the quality of
sleep and life in general, reduces days lost at work or school,
enhances productivity, reduces the use of rescue medications, and
reduces the healthcare system’s economic burden (e.g., the
number of doctors’ appointments), and society.[36] Likewise,
COPD control improves quality of life, reduces symptoms,
mental and physical dysfunction, and mortality rate.[37,38] In this
study, the primary outcome was patient-reported outcome
measure. Therefore, the study protocol was designed according
to the Standard Protocol Items: Recommendations for Interven-
tional Trials (SPIRIT-PRO) extension [39] andmapped against the
SPIRIT checklist (Appendix 1). The comparator is usual care,
defined as pharmacists’ safe supply of medicines and medication-
taking advice to the patient.
2. Objectives
2.1. Key research questions
The key research questions of this study are:
Is the pharmacist-led intervention called chronic respiratory
conditions medicines use review (CRC-MUR) provided by
community pharmacists in collaboration with physicians.
Effective in
a) Improving asthma or COPD control as assessed by the
Asthma Control Test (ACT) and Clinical COPD Question-
naire (CCQ) scores?
b) Reducing the risk of having asthma and COPD uncontrolled?
c) Optimizing the number of active ingredients used by asthma
and COPD patients?
d) Identifying and resolving pharmaceutical care issues?
e) Improving patients’ adherence to asthma or COPD medi-
cations?
f) Achieving the minimal clinically important differences
(MCID) in asthma and COPD control?
Cost-effective for
a) The healthcare system and society (compared to usual care) in
terms of cost per quality-adjusted life-year gained (QALY)
using the EuroQol five dimensions five levels (EQ-5D-5L).
2.2. Trial design
It is a pragmatic, parallel randomized controlled superiority trial
that aims to mimic routine practice as closely as possible, except
that patients will be randomly allocated to the intervention or
control group.[40] The patient follow-up period was 12months.
The study should begin in January 2022 (COVID-19 permitting).
3. Methods
3.1. Study setting
The study will be conducted in community pharmacies in
southern Italy, in one region only, Sicily, which has over 5 million
inhabitants.
3.2. Eligibility criteria
Participants will be selected according to the following eligibility
criteria:
Pharmacies must have
 a private area for private consultation with patients;
 and/or telephone, smartphone, tablet, or other devices allowing
remote consultation with their patients if required due to
COVID-19 restrictions;
 an internet connection;
Pharmacists must
 be qualified and registered with the Italian Pharmacy Board
practicing in Italy;
 have experiences in providing advice to patients;
 have already provided one or more services, such as blood
pressure monitoring, smoking cessation, cholesterol monitor-
ing, signposting, and food intolerance testing (this will be
verified during the recruitment process asking for a self-
declaration).
 be able to attend the full training session(s).
Pharmacies must be excluded if they
 have no internet access;
 no consultation room or no telephone, smartphone, tablet, or
other devices allowing remote consultation with their patients
if required due to COVID-19 restrictions;




 be at least 18 years of age;
 have been diagnosed with either asthma or COPD for at least
six months before enrollment in the study.
 have prescription(s) for asthma/COPD medications with R03
as Anatomical, Therapeutic Chemical Classification code, or
drugs for obstructive airway disease.
Patients must be excluded if they
 have a terminal illness (defined as an advanced stage of a
disease with an unfavorable prognosis and no known cure) as
identified by the pharmacists through prescription coding.
 are currently enrolled in another clinical trial;
 do not self-administer their medications (e.g. inhaler);
 are not able to communicate well in Italian, both written and
spoken.
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Tominimize diagnostic inaccuracy, asthma andCOPD diagnosis
will be reviewed in every patient at baseline, before enrollment,
following the global initiative for asthma (40) and global initiative
for chronic obstructive lung disease (GOLD) (41) strategies.
3.3. Intervention
3.3.1. Description of the intervention. The name of the
pharmacist-led intervention is CRC-MUR. Community pharma-
cists will deliver interventions in the primary care setting. The
delivery format is verbal (face-to-face or remotely using phone or
video facilities). The development of the intervention was
informed by its affordability (cost associated with the design
and delivery), practicability (pharmacists/patients), effectiveness
and cost-effectiveness, acceptability (patients/pharmacists/physi-
cians), side effects/safety (patients), consistency, and replicability.
CRC-MUR is a theoretically informed pharmacist-led interven-
tion.[41–44] It consists of a bespoke, systematic, structured face-to-
face or remote consultation (due to COVID-19) with a patient,
covering asthma/COPD symptoms, health and social care
received, medicines used, attitude towards medicines, adherence
to medication, recording pharmacist-identified pharmaceutical
care issues. If required, pharmacists advise patients, including
healthy living advice; they advise physicians on patients’
conditions using a standard template. Pharmacists will be trained
to advise patients and send recommendations to their general
practitioners and/or hospital consultants during the training
session before the beginning of the study. The CRC-MUR
intervention was mapped against the template for intervention
description and replication.[45] Following each consultation,
pharmacists will be required to enter the information on a web-
based platform, maintaining patient anonymity. The details of
the data collection are provided in Table 1 and Figure 1.
3.3.2. Control group. Patients in the control group will receive
usual care.
3.4. Criteria for discontinuing or modifying allocated
interventions
1) Participant withdraws consent
2) The trial is discontinued
3) Participant requires hospitalization
The reasons for discontinuation will be documented. Partic-
ipants will be invited to participate in an outcome-related
assessment to determine the effectiveness of the intervention.
3.5. Strategies for monitoring and improving protocol
adherence
Measures suggested to maintain and improve adherence to the
trial protocol include telephone calls, text reminders, social
support provided by community pharmacists and physicians to
their patients, and educating patients on the management of the
disease.
Community pharmacists will have to
 create a welcoming, non-judgmental, and accepting environ-
ment;
 establish an effective tracking system that will be provided by
the online web platform used for data entry.
 educate patients about their role as research participants;
 establish a routine while maintaining flexibility;
 provide incentives for participation, such as transportation,
parking spaces, home visits, and videoconferences.
3.6. Relevant concomitant care and interventions that are
permitted or prohibited during the trial
Patients were hospitalized, but overall, no other intervention
restriction was imposed in this study.
Table 1
Schedule of enrollment, intervention and assessments.
Study period
Enrollment Allocation Post-allocation Closeout
Timepoint -T0 T0 T3 T6 T9 T12
Enrollment
Eligibility screen for pharmacists x
Informed consent for pharmacists x
Eligibility screen for patients x
Informed consent for patients x
List of other procedures x
Patients’ randomization x
Intervention: it will be delivered twice to group A, after baseline and at 6 months




ACT and CCQ scores x x x x x
Number of active ingredients x x x x x
Pharmaceutical care issues x x x x x
Adherence to medications x x x x x
EQ-5D-5L x x x x x
Healthcare resource utilization x x x x x
ACT = Asthma Control Test, CCQ = Clinical COPD Questionnaire, EQ-5D-5L = EuroQol five dimensions five levels.
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3.7. Outcomes
3.7.1. Primary outcomes: Asthma and COPD control. The
primary outcomes are asthma and COPD control at baseline and
12months (according to the patients’ disease), assessed at 3-
months intervals, using the ACT score and the CCQ score.
ACT score was defined by international guidelines as
 ACT14=not controlled;
 15ACT19=partially controlled;
 ACT≥20 controlled [154].
The MCID is defined as an increase of ≥ 3-point of the ACT
score.
The CCQ was developed by van der Molen et al[46], and it
assesses COPD control according to a scale-out of ten.
The CCQ scores are defined as
 CCQ<1 = Acceptable;
 1CCQ<2=Acceptable for moderate disease (controlled);
 2CCQ3= Instable-severe limited;
 CCQ>3=Very instable-very severe limited.
The MCID is defined as a reduction of ≥0.4 points of the CCQ
score. Furthermore, the CCQ assesses three main domains:
Symptoms= (Item 1+2+5+6)/4, Functional= (Item 7+8+9+
10)/4, Mental= (Item 3+4)/2.[38]
3.7.2. Justification for the use of ACT and CCQ. The ACTwas
previously used in Italy in a study conducted by the Italian Society
of General Medicine (Societá Italiana di Medicina Generale) and
in the I-MUR study. The International Primary Care Respiratory
Group proposed creating a user’s guide for primary healthcare
practitioners to assess “wellness” in COPD patients in an
everyday clinical setting. They ranked the CCQ as the most
recommended among the eight questionnaires examined in their
study.[47] Moreover, the CCQ was used in another study by a
member of our research team.[48]
3.7.3. Secondary outcomes.
1. Reduction of the risk of having asthma and COPD
uncontrolled, assessed using the ACT and CCQ scores
assessed at baseline and 3-month intervals, as reported by
patients.
2. The number of active ingredients used by patients at baseline
and 12months assessed at 3-month intervals, as reported by
patients.
Assess for patients’ eligibility (n =)
Randomized (n= 900)
Excluded not meeting the selection criteria
(n= )
Declined to participate (n ==)





Group A (n=600 )






















Baseline , ACT/CCQ, NAI, AM, PCI, EQ5D5L 
CRC-MUR
Month 3, ACT/CCQ, NAI, AM, PCI, EQ5D5L 
Month 6, ACT/CCQ, NAI, AM, PCI, EQ5D5L 
CRC-MUR
Month 12, ACT/CCQ, NAI, AM, PCI, EQ5D5L 
Month 9, ACT/CCQ, NAI, AM, PCI, EQ5D5L
Group B (n=300 )
(allocated to control: usual care)
Baseline , ACT/CCQ, NAI, AM, PCI, EQ5D5L
Month 3, ACT/CCQ, NAI, AM, PCI, EQ5D5L 
Month 6, ACT/CCQ, NAI, AM, PCI, EQ5D5L
Month 9, ACT/CCQ, NAI, AM, PCI, EQ5D5L
Month 12, ACT/CCQ, NAI, AM, PCI, EQ5D5L 
Analyzed (n= )
Excluded from analysis (give reasons) (n = )
Figure 1. CONSORT flowchart of the study design. ACT = asthma control test, AM = adherence to medications, CCQ = clinical COPD questionnaire, EQ5D5L =
EuroQol, NAI = number of active ingredients, PCI = pharmaceutical care issue.
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3. Patients’ self-reported adherence to asthma/COPD medica-
tions at baseline and 12months assessed at 3-month intervals
using the questions used in the I-MUR study.
4. Pharmaceutical care issues at baseline and 12months assessed
at 3-month intervals using the questions used in the I-MUR
study.
5. TheMCID in ACT and CCQ scores at baseline and 12months
assessed at 3-month intervals, as reported by the patients.
6. Cost-effectiveness of CRC-MUR asthma/COPD service com-
pared with usual care, measured in terms of cost per QALY as
ameasure of disease burden, including both the quality and the
quantity of life gained, at the 12-month follow-up.
3.7.4. EQ-5D-5L. The EQ-5D-5L questionnaire will be used to
measure health-related quality of life at baseline and at each
subsequent 3-month data collection time point. The EQ-5D-5L
was selected for use in calculating QALYs using Italian utility
tariffs. It is more “sensitive” than the 3-level version, including
dimensions of anxiety and depression and daily activities that may
have been impacted by the COVID-19 pandemic. Individual
patient data on visits to the GP and outpatient departments,
attendance to the Accidents and Emergency department, hospital
admissions, and medication will be retrieved from electronic
patient records for the 12-month follow-up. The Italian unit costs
of these services are used to monetize resource use into costs. Trial
management will provide intervention costs allocated to each
patient in the intervention armusing a top-down costing approach.
3.8. Participant timeline
Pharmacists will encounter their patients at baseline (T0) and
every three months. Table 1 was designed according to the
SPIRIT 2013;[49] summarizes the enrollment, intervention, and
assessment schedule.
3.9. Sample size
The power calculation was conducted using the z-test family,
calculating the proportion of the difference between two
independent groups with two tails using the dichotomized scores
of ACT and CCQ: controlled (ACT≥20; CCQ<2) versus non-
controlled (ACT<20; CCQ≥2). A 2:1 randomization and sample
size of 887 patients (591 in the IG and 296 in the control group
[CG]) will be enough to detect a difference of 15% between the
intervention and control groups using a dichotomized score
(controlled vs. non-controlled) of the ACT/CCQ, a 99% power
and 5% significance level. The 15% difference represents the
difference between the percentage of controlled (65%) and non-
controlled (50%) patients at the end of the study. The power
calculation was conducted using G∗Power version 3.1.9.4; the
results were assessed and confirmed by a senior statistician
working at the UCLan’s Clinical Trial Unit.
3.9.1. Recruitment. We decided to round up the number for
simplicity; therefore, we aim to recruit 100 pharmacists and 900
consecutive patients (asthma=450; COPD=450). Our recruit-
ment strategy will focus on increasing potential participants’
awareness of the health problem being studied, its potential
impact on their health, and engagement in the learning process.
3.9.2. Pharmacist patient ratio. The pharmacist-patient ratio
was 1:9, meaning that each pharmacist will recruit and follow-up
nine patients.
3.10. Randomization, sequence generation, allocation and
blinding
3.10.1. Randomization.An academic from the UCLan expert in
the use of statistics will oversee the randomization process. The
randomization procedure was simplified as follows. Thus, the 2:1
allocation was rounded up to 600 in the intervention group
(instead of 591) and 300 in the control group (instead of 296)
(Fig. 1). The 2:1 randomization was requested by the lead
clinician, who reviewed the results of the I-MUR study and did
not want to prevent patients from getting the potential benefits
from the intervention.
3.10.2. Unit of randomization and intervention. The patient is
the unit of randomization and intervention.
3.10.3. Block size. The choice of using the block equal to nine
will be adopted because large blocks reduce predictability but will
not restrict randomization as closely as small blocks.
3.10.4. Sequence generation. Sequence generation will be
conducted using block permutation without stratification,
followed by randomization, owing to the expected large sample
size (n=900), as suggested by the senior statistician of the
Lancashire Clinical Trial Unit (LCTU). The procedure will be
performed by a member of the research team at UCLan using the
sealed envelope online system.
3.10.5. Allocation concealment. Allocation concealment will
be performed by a member of the research team using the sealed-
envelope online system, which generates an allocation schedule.
In this study, two lists will be produced. The first list will be given
to the pharmacist before patient recruitment, where a unique
three-digit code (e.g., relative risk 3, TS7, VS5) will be assigned to
each participant. A second list will be released at the end of the
recruitment process and will allocate each three-digit code
(participant) to either IG or CG. This approach will be adopted
because it will not be possible to produce 900 sealed envelopes
and circulate them on the starting date (before baseline) while
maintaining the cost within the allocated budget.
3.10.6. Blinding. In our study, blinding will not be possible
either at the pharmacist or patient level because the nature of the
intervention requires their full knowledge. However, the chief
investigator (CI), as an assessor of the main outcome measures,
asthma and COPD control, will remain blind. As group
allocation is intrinsic to the data gathered for each patient, to
maintain blindness, the CI will access the data only after all
patients have been followed up at three months (see Table 1).
Friedman et al[50] suggested that an unblinded trial might not be
simple, but it more accurately reflects clinical practice.
3.11. Data collection
Data will be collected by the pharmacists at baseline and 3-month
intervals using a bespoke web platform (FarmPro) already in use
in many pharmacies in Sicily following the procedure illustrated
in Table 1 and Figure 1. All questionnaires will be available in
two languages: Italian and English. The CI is proficient in both
languages and has translated the CRC-MUR from English to
Italian. Another member of the research team, proficient in both
languages, has back-translated CRC-MUR into English, and the
two English versions were compared to avoid discrepancies.
ACT, CCQ, and EQ-5D-5L are also available in English and
Italian. A small test will be conducted during the summer of 2020
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to verify that the platform will respond to all requirements. The
platform will allow the use of different digital devices, such as
personal computers,, laptops, tablets, and smartphones. The
platform also complies with the General Data Protection
Regulation (GDPR) procedure. Primary and secondary outcomes
were collected according to the timeline of the study. The length
of the patient consultation was expected to be between 30 and 45
minutes. A small number (subgroup) of COPD patients (n=45),
30 in the IG and 15 in the CG, will have their vital signs
monitored using a wearable device named Health REmote
MOnitoring System (HEREMOS). The vital signs monitored will
be heart rate, respiratory rate, and saturation of peripheral
oxygen. Additionally, body temperature, blood pressure, heart
rate variability, step count, and pain may be included.
Furthermore, we will capture pollen concentration, air pollution
(108), particulate matter 10 micrometers or less in diameter, and
sulfur dioxide. Monitoring will mostly take place at the patients’
home premises and during patient consultation when necessary.
3.12. Data management
Data will be managed following the procedure used in a previous
study.[29] Input data will be saved and stored on a password-
protected system. Only individuals authorized by the CI will be
allowed to access the data. Paper data, such as pharmacists’
informed consent, will be kept in a locked cabinet by the research
team. Patients’ informed consent will be kept in a locked cabinet
by the pharmacists.
3.13. Statistical methods
The primary analysis will be the intention-to-treat, including all
randomized participants in the group where they were randomly
assigned, regardless of their adherence to the protocol or their
withdrawal.
Missing data: The previous experience of the CI suggests that
data will be missing at random (MAR); therefore, multiple
imputations will be applied.
Each variable will be analyzed using the Shapiro-Wills and
Kolmogorov-Smirnov test to check for normality.
Primary outcomes: The primary outcome measures will be
dichotomized, controlled (ACT≥20; CCQ<2) and not controlled
(ACT<20; CCQ≥2) and analyzed using generalized estimating
equations (GEEs) at 12months. The GEE model will be used to
calculate the odds ratio and 95% confidence interval (CI) without
adjustment. It will then be adjusted using the ACT/CCQ values
obtained at baseline, sex, and age. The relative risk, relative risk
reduction,absolute risk reduction,andnumberneeded to treatwillbe
calculated. The proportion of controlled and non-controlled patients
will be presented using descriptive statistics at each time point.
Secondary outcomes: Survival analysis will be conducted using
the Kaplan-Meier curve, with the log-rank (Mantel-Cox) option,
aiming to estimate the survival curve, using the ACT/CCQ
control as the event of interest. The risk of uncontrolled disease
will be estimated using Cox regression. The mean/median
number of active ingredients and PCI will be assessed at each
time point using either the unpaired Student t-test or Mann
Whitney U test; GEE at 12months. Adherence to medications
andMCID will be assessed, dichotomizing the variable (adherent
and non-adherent; MCID yes or no); the analysis will be
conducted using Pearson chi-square or Fisher exact test at each
time point and GEEs at 12months.
An economic evaluation will be undertaken to assess the cost-
effectiveness of CRC-MUR at 12months. Cost effectiveness will
be expressed in terms of incremental cost per QALY gained.
Bootstrapping will be performed to address uncertainty in the
estimates. Uncertainty will be displayed in cost-effectiveness
planes and cost-effectiveness acceptability curves.
Method for additional analysis: A small cohort of COPD
patients (30 in the IG and 15 in the CG) will have their vital
parameters monitored through the smart sensors of the HERE-
MOS platform. The data collected: Saturation of Peripheral
Oxygen, respiratory rate, heart rate, blood pressure, body
temperature, heart rate variability, step count, and pain will be
analyzed with the help of machine learning technology.
Additionally, the patients’ data collected through the study
questionnaires will be included in the analysis. Different
classification techniques, such as support vector machines and
random forests, will be considered to evaluate the level of disease
control.
Statistical significance was set at P<0.05. In addition, the effect
size between the two groups and the 95% confidence interval will
be reported (when appropriate). Data analysis will be performed
using the SPSS 27 (IBM).
3.14. Data monitoring
This trial was designed to minimize the risk, as demonstrated in a
previous trial.[29] Therefore, no formal committee has been
organized, and no interimanalysis of the impact of the intervention
has been planned. The coordinating center for the study in Italy is
the Catania Policlinico (Hospital), supported by UCLan.
3.15. Risk and safety issues
During this study, there will be no risks for the patients. Patients
receiving the CRC-MUR service will be at no greater risk than
those receiving usual care. Pharmacists will not dispense or
administer any medications based on the ACT, CCQ, EQ-5D-5L
scores, or CRC-MUR results. Pharmacists will not be involved in
the interpretation of diagnostic tests or their results.
3.16. Harm
We do not expect adverse events or other unintended effects. All
information regarding the trial will be included in the
pharmacists’ and patient information sheets. Patients using the
remote monitoring systemHEREMOSwill not be exposed to any
harm. The HEREMOS sensor system is intended for the sole
purpose of monitoring vital signs. This system is not intended for
use in cardiac pacemakers. In addition, the system is not intended
for use during anMRI scan or when using an internal or external
defibrillator. Strong electromagnetic fields can damage the system
and make it dangerous.
3.17. Auditing
No audit has been planned at this time.
4. Research and dissemination
4.1. Research ethics approval
Ethics approval was obtained from the Catania Ethics Committee
(Italy) (ref. 47/2021/PO; February 22nd, 2021), and the
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University of Central Lancashire (UK) (ref HEALTH 0163;
March 29th, 2021).
4.2. Protocol amendments
We are not expecting to make any changes to the eligibility
criteria, outcomes, and analyses during our study.
4.3. Consent, invitation and confidentiality
All documentation related to information and consent for
pharmacists and patients has been enclosed in the protocol and
approved by the ethics committees in Italy and the UK. The
procedures followed for consent and confidentiality are described
in the following paragraphs.
4.3.1. Informed consent. The chief investigator (CI; AM)
obtained consent from the participating pharmacists.
Participating pharmacists will recruit their patients and obtain
consent from them.
4.3.2. Who will write to the pharmacists?. An invitation letter
and a summary of the study will be prepared by the CI and sent to
SOFAD and Federfarma Sicilia, which will distribute the letter
with information regarding the study to all community
pharmacists in all the identified locations inviting pharmacists
to participate in the study.
4.3.3. How will pharmacists consent?. Pharmacists who
express interest in participating will be invited to attend
presentations. At presentation, which will take place between
January and February 2022 (COVID permitting), the CI will
outline the study protocol and enrollment criteria. Participants
received a detailed participant information sheet. The president
of SOFAD and Federfarma Sicilia will collate the names of
pharmacists who will express interest over the next few weeks.
The first 100 pharmacists who met the inclusion criteria will be
selected for inclusion in the study.
4.3.4. Patients’ recruitment and informed consent. After
assessing patients’ eligibility for the study, pharmacists will
provide an information letter and consent form to each patient,
who will get a week to consider their participation. The
pharmacist will retain all signed consent forms in the pharmacy
in a locked cabinet.
4.3.5. Confidentiality. Written informed consent will be
obtained from all participants included in the study. All data
will be handled following the requirements of the Data Protection
Act (2018) and/or the GDPR 2016, according to European Union
law. Therefore, the data will be anonymized and stripped of any
identifiable reference to the participants.
4.3.6. Declaration of interest. None
4.3.7. Dissemination policy.The dissemination of the studywill
begin immediately after the publication of the protocol. Then, it
will continue throughout the study using social media posts,
patient events, the third sector, and public engagement events.
The results of this trial will be presented at national and
international conferences. They will be submitted as scientific
manuscripts to peer-reviewed journals, and subsequently pub-
lished in non-peer-reviewed publications in Italian and maybe
other languages. The trial results aim to inform policymakers, the
Italian Ministry of Health, the Italian National Health Services,
and all other stakeholders that might benefit from the results. The
results will be disseminated to service users and their families via
media, healthcare professionals via professional training and
meetings, and to researchers via conferences and publications.
4.3.8. Ancillary and post-trial care. We are not envisaging the
need for the provision of post-trial care. Nevertheless, all
participants will be provided with an emergency contact number
to reach the study investigators so that they can receive the
necessary support when they have any questions or problems.
4.3.9. Plans, if any, for granting public access to the full
protocol, participant-level data set, and statistical code. The
research team aims to publish the research protocol before
starting the trial in a gold open-access journal. Therefore,
everyone will have free access to trial protocols. Once the study is
completed and the main paper submitted for publication, the data
set will be available at the University of Central Lancashire’s
repository, and all data will be anonymized in line with GDPR
requirements.
5. Patient and public involvement
The research team developed a protocol during the COVID-19
outbreak (February-July 2020). Hence, it was not possible to
organize meetings with patients to obtain their views and
opinions. Therefore, the research team contacted Active
Citizenship (Cittadinanza Attiva), an Italian national body
looking after patients’ health and safety. They assessed the
research protocol considering its clarity and patients’ overall
burden during the study, providing positive feedback, and
praising the initiative.
6. Discussion
Many studies conducted in community-pharmacy settings have
assessed the effectiveness and cost-effectiveness of pharmacist-led
interventions. However, there is a lack of consistency in the
intervention designs and assessments. In Italy, the only study that
used a randomized controlled trial design to assess the
effectiveness and cost-effectiveness of a pharmacist-led interven-
tion in a chronic condition. To the best of our knowledge, this is
the first study conducted in Italy, aiming to assess pharmacists’
contribution to improving disease control in two very common
chronic lung conditions: asthma and COPD. It is one of the
largest studies conducted in one region, and it introduces a new
systematic and quantitative bespoke research instrument, CRC-
MUR. In Italy, it appears to be the first RCT protocol drafted
according to the SPIRIT-PRO extension guidelines,[39] assessing
the effectiveness and cost-effectiveness of a pharmacist-led
intervention delivered by community pharmacists during and
after the COVID-19 outbreak. The effect of COVID will be long-
lasting and will impact the healthcare system and the availability
of patients’ appointments with their general practitioners (GPs).
Thus, this intervention aims to reduce GPs’ workloads, allowing
them to concentrate on more serious conditions, such as cancer.
Furthermore, this study will test the intervention and evaluate
a model that can be adapted to other chronic conditions if
successful.
The study included only adults and patients who will be
followed up for 12months. Given the study’s size, we anticipate
that problems may arise, for example, due to COVID-19, with
the pharmacist and patient recruitment, resulting in the loss of
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power. However, we considered this in our power calculation by
evaluating two possible options based on the actual results of our
previous studies. A potential/expected drop-out rate has already
been factored into the power calculation. Assuming that we aim
to recruit 900 consecutive patients, we expect a dropout rate of
25% (n=225 patients) in an unlikely scenario. The number of
participants will then be reduced to 675, but the study will still
retain 96% of the power. In the worst-case scenario, if the
number of participants dropped to 413, the study retained 90%
of the power.
7. Conclusions
This is the first study conducted in Italy to assess the effectiveness
and cost-effectiveness of a pharmacist-led intervention in asthma
andCOPDpatients at the same time. The potential benefits of this
study are multifold. Thus, the intervention could 1) improve
patients’ quality of life, 2) reduce the cost to the national
healthcare service and society, 3) upskill community pharmacists,
4) introduce a new remuneration scheme for such services, 4)
contribute to better integration of community pharmacies in the
primary healthcare team, and 5) free up physicians’ time to allow
them to concentrate on other difficult conditions. This research
could introduce a new model of care that can be adapted to other
chronic conditions in primary care settings.
8. Protocol version
The study protocol version was 1.1.1; 30.09.2020. Important
amendments to the study protocol or other changes will be
periodically updated at the trial registration site.
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